مشخصات پژوهش

The rising prevalence of cardiovascular disease (CVD) globally highlights the urgent need for effective treatment strategies, particularly as CVD remains the leading cause of death worldwide. Traditional therapies, such as statins, often fall short for many patients due to intolerance or inadequate LDL-C reduction, creating a demand for innovative alternatives like proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i). This research is essential to understand the clinical implications of PCSK9i therapy and its impact on various biochemical markers, including troponin, hemoglobin, erythrocyte sedimentation rate (ESR), and fasting blood sugar (FBS), which provide insights into myocardial injury, inflammation, and metabolic health. Investigating these relationships is crucial for optimizing treatment strategies and enhancing patient care, as it can inform clinical decision-making and help identify patients who may benefit most from PCSK9i therapy. Additionally, this research aligns with the growing emphasis on personalized medicine, where a comprehensive assessment of multiple biochemical markers can lead to tailored treatment approaches. Ultimately, this study aims to address critical gaps in CVD management, improve understanding of cardiovascular health, and foster more effective and individualized care for patients.